[China BD 2024] ImmuneOnco and Instil Bio Enters a 2.05 billion USD License on two mAb Assets, PD-L1xVEGF Bispecific Antibody IMM2510 and Anti-CTLA-4 Antibody IMM27M

Announced Date: 2024-08-01 (August 1, 2024)

Asset Name: IMM2510 and IMM27M

Licensor: ImmuneOnco Biopharmaceuticals (Shanghai) (China)

Licensee (Buyer): Instil Bio (USA)

.

Asset 1: IMM2510 (SYN-2510, AXN-2510)

Asset Modality: BsAbs (Bispecific antibody)

Asset Target: PD-L1xVEGF

anti-PD-L1 antibody fused to a vascular endothelial growth factor (VEGF) receptor “trap” which binds VEGF.

Potential Indication: Multiple Solid tumors, Non-Small Cell Lung Cancer (NSCLC) and Triple-Negative Breast Cancer (TNBC)

Current Stage: Phase I

.

Asset 2: IMM27M

Asset Modality: antibody

Asset Target: CTLA-4 

Potential Indication: solid tumors

Current Stage: Phase I

.

Scope of Authority:

Instil will receive global development and commercialization rights for IMM2510 and IMM27M outside of Greater China.

while ImmuneOnco will retain development and commercialization rights in Greater China including Taiwan, Macau, and Hong Kong. 

.

Payment Detail:

ImmuneOnco will receive:

Upfront payment and potential near-term payments of up to $50 million,

Potential additional development, regulatory, and commercial milestones exceeding $2 billion,

Single digit to low double-digit percentage royalties on global ex-China sales.

.

Link:

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody | Instil Bio

.

Note:

Chinese Name of ImmuneOnco Biopharmaceuticals (Shanghai)  宜明昂科（上海）